Michael J. Thirman

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

May, 2025

Michael J. Thirman

Jan 4, 2025, 15:18 | Insight

Vivek Subbiah: Top Phase 1 clinical trial publications of 2024

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared…

Dec 23, 2024, 11:55 | Drugs

Talha Badar: Venetoclax and Azacitidine for elderly AML ineligible for intensive Induction

Talha Badar shared on X: “Brief overview of venetoclax+azacitidine for elderly AML ineligible for intensive…

Aug 14, 2024, 07:20 | Drugs

Keith W Pratz: Novel risk signature for AML treated with Azacitidine and Venetoclax

Keith W Pratz, Director of Leukemia at the Hospital of University of Pennsylvania, shared on…

Aug 12, 2024, 01:35 | Blog

Joshua Zeidner: Highly impactful data for R/R AML and menin inhibitors

Joshua Zeidner, Associate Professor at UNC Lineberger, shared a post by Ghayas Issa, Leukemia Physician at MD…

All: 4 Posts: 1 - 100

'

Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football

'

Yvonne Award for Breakthrough Research 2024 Recipient to Time100 Health List

'

Dr Saunthari Somasundaram is the new President-Elect of the NCD Alliance

'

Does Plastic Cause Cancer? Myths and Facts

'

TOPGEAR trial at ESTRO 2025: Preoperative Chemoradiotherapy for Resectable Gastric Cancer

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023